clinical trial · NCT04725240
Open-Label Study of Setmelanotide in Hypothalamic Obesity
Hypothalamic ObesitySetmelanotide
brief summary
Open-label, single-arm study designed to evaluate the body weight response to setmelanotide administered subcutaneously (SC) daily in participants with hypothalamic obesity (HO).
started
Jun 7, 2021
primary completion
Jun 28, 2022
completion
Jun 28, 2022
last updated
Feb 7, 2025
official title
A Phase 2, Open-Label 20-Week Study to Evaluate the Safety and Efficacy of Setmelanotide in Subjects With Hypothalamic Obesity
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol